Kristen Marks, M.D.

Dr. Marks is an Associate Professor of Medicine at Weill Cornell Medicine (WCM) where she conducts clinical trials related to HIV, HCV and COVID prevention and treatment. She received Internal Medicine residency and Infectious Diseases fellowship training at New York-Presbyterian Hospital (Cornell), where she focused clinical training and research on HIV and hepatitis virus infections and completed Weill Cornell's Master's Degree in Clinical Investigation. She has taken a leadership role advancing the treatment of HIV and hepatitis C in various populations at Cornell through clinical, education, and research activities. Her current research focuses on improving treatment outcomes in patients with HIV and hepatitis virus co-infections. Several research projects have focused specifically on people who inject drugs including an ongoing R01-funded study comparing HCV treatment delivery at a community syringe exchange program with usual care. She is the co-chair of an AIDS Clinical Trials Group (ACTG) multi-center study to assesses a novel Hepatitis B vaccine, currently serve on three ACTG protocol teams, and is a member of the ACTG Hepatitis Transformative Science Group. She serves as a co-director of the Cornell HIV/AIDS Clinical Trials Unit, where she conducts several treatment studies related to HIV and hepatitis viruses. She served as co-chair of IDSA/AASLD's joint guidelines panel for "Recommendations for testing, managing and treating hepatitis C" and as a member of New York State's HCV guidelines panel. When the COVID pandemic hit New York City, she led the phase 3 studies of remdesivir at Weill Cornell as well as a phase 3 studies of a vaccine for the prevention of COVID.